We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

48 hedge funds and large institutions have $19.3M invested in Carisma Therapeutics in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

0% more funds holding

Funds holding: 48 → 48 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

0.76% less ownership

Funds ownership: 1.97% → 1.21% (-0.76%)

55% less capital invested

Capital invested by funds: $43.3M → $19.3M (-$24M)

Holders
48
Holders Change
–
Holders Change %
0%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
11
Reduced
8
Closed
14
Calls
$37K
Puts
–
Net Calls
+$37K
Net Calls Change
-$73K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$720K
2
Bank of America
Bank of America
North Carolina
+$216K
3
CHP
Castle Hook Partners
New York
+$216K
4
BCM
BlueCrest Capital Management
Jersey
+$108K
5
BCM
Bridgeway Capital Management
Texas
+$86.3K

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$10.7M
2
DCM
Driehaus Capital Management
Illinois
-$4.73M
3
SSA
Schonfeld Strategic Advisors
New York
-$1.35M
4
Millennium Management
Millennium Management
New York
-$911K
5
DS
DRW Securities
Illinois
-$492K
Name Holding Trade Value Shares
Change 		Change in
Stake
FT
26
Fiduciary Trust
Massachusetts
$21K – – –
AAP
27
Ardsley Advisory Partners
Connecticut
$21K +$17.7K +1,025 New
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Quebec, Canada
$20.6K +$17.3K +1,000 New
Citadel Advisors
29
Citadel Advisors
Florida
$17K -$22K -1,276 -61%
Creative Planning
30
Creative Planning
Kansas
$14K – – –
UBS Group
31
UBS Group
Switzerland
$13K +$9.43K +546 +738%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$11K – – –
AWM
33
AE Wealth Management
Kansas
$10K +$8.63K +500 New
SS
34
Simplicity Solutions
Minnesota
$10K +$8.63K +500 New
HFM
35
Hartford Financial Management
Connecticut
$4K – – –
Morgan Stanley
36
Morgan Stanley
New York
$2K -$1.8K -104 -53%
AG
37
Advisor Group
Arizona
$2K – – –
Wells Fargo
38
Wells Fargo
California
$2K – – –
APA
39
American Portfolios Advisors
New York
$1.03K – – –
CHP
40
Cable Hill Partners
Oregon
$1K -$863 -50 -50%
Citigroup
41
Citigroup
New York
$1K – – –
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$1K – – –
TWA
43
TCI Wealth Advisors
Arizona
$1K +$604 +35 +140%
SWM
44
SeaCrest Wealth Management
New York
$1K +$1.07K +62 New
CCM
45
Consonance Capital Management
New York
– -$10.7M -376,165 Closed
DCM
46
Driehaus Capital Management
Illinois
– -$4.73M -166,612 Closed
SSA
47
Schonfeld Strategic Advisors
New York
– -$1.35M -47,518 Closed
DS
48
DRW Securities
Illinois
– -$492K -17,335 Closed
PVI
49
Pura Vida Investments
New York
– -$284K -10,000 Closed
OAM
50
Oxford Asset Management
United Kingdom
– -$244K -8,602 Closed
1
2
3

CARM Hedge Fund Activity: Q1 2019 in Review

48 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2019, worth a combined $19.3M — down 55% from $43.3M a quarter earlier.

Fund positioning in CARM was balanced in Q1 2019: 14 funds opened new positions, 14 closed out, 11 added to existing stakes and 8 trimmed.

The largest buyer was Vanguard Group, adding an estimated $720K. The largest seller was Consonance Capital Management, exiting entirely with an estimated $10.7M sold.

  • 48 institutional investors held Carisma Therapeutics (CARM) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $19.3M of Carisma Therapeutics stock for Q1 2019, down 55% quarter-over-quarter.
  • 14 funds opened new Carisma Therapeutics positions in Q1 2019 and 14 closed out, a net change of 0 holders.
  • The largest Carisma Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $720K added.
  • The largest Carisma Therapeutics seller in Q1 2019 was Consonance Capital Management, an estimated $10.7M sold.

Based on aggregated 13F filings for Q1 2019.